The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

Two names immediately came to mind: BeiGene and Legend Biotech. The companies share some similarities. Although not named in the BIOSECURE legislation, both firms have deep China links ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...